Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18414147 | TREATMENTS WITH NIROGACESTAT | January 2024 | May 2024 | Allow | 4 | 1 | 0 | No | No |
| 18400333 | [4,4-BIS(4-NITROPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]ACETIC ACID AS AN ANTIMICROBIAL COMPOUND | December 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18543022 | TREATMENTS WITH NIROGACESTAT | December 2023 | May 2024 | Allow | 5 | 1 | 0 | No | No |
| 18491225 | TREATMENTS WITH NIROGACESTAT | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18491283 | TREATMENTS WITH NIROGACESTAT | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18491525 | TREATMENTS WITH NIROGACESTAT | October 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18491323 | TREATMENTS WITH NIROGACESTAT | October 2023 | May 2024 | Allow | 7 | 1 | 0 | No | No |
| 18491379 | TREATMENTS WITH NIROGACESTAT | October 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18484393 | 2-(BENZO[D]OXAZOL-2-YL)-N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18371092 | SYNTHESIS OF THIOSEMICARBAZIDE ANALOGUE AS INHIBITOR OF TYROSINASE, SKIN HYPERPIGMENTATION, AND FRUIT AND/OR VEGETABLE BROWNING | September 2023 | February 2024 | Allow | 5 | 1 | 0 | No | No |
| 18457725 | 3,3',3"-NITRILOTRIS(1-(NAPHTHALEN-2-YLOXY)PROPAN-2-OL) AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | August 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18239495 | N'-[(4-CHLOROBENZOYL)OXY]-1,3-BENZOTHIAZOLE-2-CARBOXIMIDAMIDE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18361884 | TREATMENTS WITH NIROGACESTAT | July 2023 | January 2024 | Allow | 6 | 1 | 0 | No | No |
| 18357988 | TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB | July 2023 | April 2024 | Allow | 9 | 1 | 0 | No | No |
| 18224223 | NOVEL NANO-SIZED 5,10,15,20-TETRAKIS (4-HYDROXYPHENYL)- PORPHYRINS PD(II) COMPLEX FOR SUPER MEDICINAL APPLICATIONS | July 2023 | December 2023 | Allow | 5 | 1 | 0 | No | No |
| 18355554 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | July 2023 | October 2023 | Allow | 3 | 1 | 0 | No | No |
| 18220742 | SYNERGISTIC CANCER TREATMENT | July 2023 | September 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18215727 | SOLID FORMS OF ((S)-5-((1-(6-CHLORO-2-OXO-1,2-DIHYDROQUINOLIN-3-YL)ETHYL)AMINO)-1-METHYL-6-OXO-1,6-DIHYDROPYRIDINE-2-CARBONITRILE | June 2023 | April 2024 | Allow | 10 | 1 | 0 | No | No |
| 18327986 | 1,4-Substituted Piperidine Derivatives | June 2023 | June 2024 | Allow | 13 | 1 | 0 | No | No |
| 18323232 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | May 2023 | November 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18323236 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | May 2023 | November 2023 | Allow | 6 | 1 | 0 | No | No |
| 18320547 | TREATMENTS WITH NIROGACESTAT | May 2023 | November 2023 | Allow | 6 | 2 | 0 | No | No |
| 18315723 | METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | May 2023 | January 2024 | Allow | 9 | 0 | 0 | No | No |
| 18195506 | Compositions And Methods For Oral Delivery Of Crystalline PRX-3140 Potassium Salt | May 2023 | March 2024 | Allow | 10 | 2 | 0 | No | No |
| 18122496 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | March 2023 | April 2024 | Allow | 13 | 1 | 0 | No | No |
| 18185080 | TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB | March 2023 | July 2023 | Allow | 4 | 1 | 0 | No | No |
| 18112308 | PHARMACEUTICAL FORMULATIONS | February 2023 | April 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18110517 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | February 2023 | June 2023 | Allow | 4 | 1 | 0 | No | No |
| 18168204 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | February 2023 | December 2023 | Allow | 10 | 1 | 0 | No | No |
| 18106339 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | February 2023 | June 2023 | Allow | 4 | 1 | 0 | No | No |
| 18163117 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | February 2023 | December 2023 | Allow | 10 | 1 | 1 | No | No |
| 18092731 | POLYMORPHS OF ARRY-380, A SELECTIVE HER2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | January 2023 | May 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18091088 | COMPOSITION INCLUDING RILPIVIRINE AND METHOD FOR TREATING TUMORS OR CANCER | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18076992 | USE OF AN RXR AGONIST AND TAXANES IN TREATING HER2+ CANCERS | December 2022 | July 2023 | Allow | 8 | 0 | 1 | No | No |
| 18061610 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | December 2022 | February 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18061239 | METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | December 2022 | April 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 17990722 | DEUTERATED ANALOGS OF ELACRIDAR | November 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 17985297 | Method for Treating Cancerous and Pre-Cancerous Skin | November 2022 | June 2023 | Allow | 7 | 1 | 0 | No | No |
| 17985326 | Method for Treating Cancerous and Pre-Cancerous Skin | November 2022 | July 2023 | Allow | 8 | 1 | 0 | No | No |
| 18052369 | METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS | November 2022 | January 2024 | Allow | 14 | 1 | 0 | No | No |
| 17975645 | METHODS OF INACTIVATION OF VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES | October 2022 | March 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18048015 | COMPOSITIONS AND METHODS TO TREAT CANCER | October 2022 | May 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18047078 | METHODS AND COMPOSITIONS FOR TREATING CANCER | October 2022 | January 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 17966504 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | October 2022 | April 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 17944922 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | September 2022 | April 2023 | Allow | 7 | 1 | 0 | No | No |
| 17799291 | COMPOUND ISOLATED FROM TORILIDIS FRUCTUS, AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | August 2022 | January 2023 | Allow | 5 | 0 | 0 | No | No |
| 17796258 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | July 2022 | June 2024 | Allow | 22 | 1 | 0 | No | No |
| 17860889 | USE OF BELINOSTAT OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PREPARATION OF DRUG FOR TREATING INFECTION | July 2022 | May 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 17855847 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | July 2022 | June 2024 | Allow | 23 | 1 | 0 | No | No |
| 17851399 | CHEMOTHERAPEUTIC SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEMS AND USES THEREOF | June 2022 | September 2022 | Allow | 2 | 0 | 0 | No | No |
| 17809190 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | June 2022 | March 2024 | Allow | 20 | 1 | 0 | No | No |
| 17833745 | Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels | June 2022 | December 2022 | Allow | 6 | 2 | 0 | Yes | No |
| 17830519 | COMPOSITIONS AND METHODS FOR ORAL DELIVERY OF CRYSTALLINE PRX-3140 POTASSIUM SALT | June 2022 | March 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 17828255 | USE OF SMALL MOLECULE BASED ON INDOTRICARBOCYANINE STRUCTURE IN PREPARATION OF MEDICINES FOR TUMOR PHOTOTHERMAL THERAPY | May 2022 | January 2023 | Allow | 7 | 1 | 0 | No | No |
| 17779649 | POLYETHYLENE GLYCOL CONJUGATE MEDICAMENT, PREPARATION METHOD THEREFOR AND USE THEREOF | May 2022 | April 2023 | Allow | 11 | 1 | 0 | No | No |
| 17661909 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | May 2022 | November 2023 | Allow | 18 | 1 | 0 | No | No |
| 17712585 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | April 2022 | April 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17700168 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | March 2022 | November 2022 | Allow | 7 | 3 | 1 | No | No |
| 17580077 | METHODS AND COMPOSITIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS | January 2022 | February 2024 | Allow | 25 | 1 | 0 | No | No |
| 17571411 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | January 2022 | September 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17565579 | METHODS OF TREATING SPLENOMEGALY | December 2021 | November 2022 | Allow | 11 | 1 | 0 | Yes | No |
| 17553564 | CATIONIC LIPIDS AND TRANSFECTION METHODS | December 2021 | August 2023 | Allow | 20 | 1 | 0 | No | No |
| 17511044 | TARGETING RNA VIRUSES USING INHIBITORS OF METTL3 | October 2021 | November 2023 | Allow | 25 | 1 | 1 | No | No |
| 17501407 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | October 2021 | December 2023 | Allow | 26 | 1 | 0 | No | No |
| 17602331 | NOVEL COMPOUND HAVING PD-L1 EXPRESSION-SUPPRESSING ACTION | October 2021 | October 2022 | Allow | 13 | 1 | 0 | No | No |
| 17494230 | METHODS OF TREATING VIRAL INFECTIONS AFFECTING THE RESPIRATORY TRACT USING TOPICALLY ADMINISTERED LITHIUM AGENTS | October 2021 | August 2023 | Allow | 22 | 0 | 0 | No | No |
| 17494517 | COMPOSITION INCLUDING RILPIVIRINE AND METHOD FOR TREATING TUMORS OR CANCER | October 2021 | September 2022 | Allow | 12 | 2 | 0 | No | No |
| 17273102 | COMPOSITE FORMULATION AND USE THEREOF FOR PREPARING DRUGS FOR THE TREATMENT OF TUMOURS | September 2021 | June 2022 | Allow | 15 | 1 | 0 | No | No |
| 17478192 | CARBOXYLIC ACID AROMATIC AMIDES | September 2021 | February 2024 | Allow | 29 | 2 | 0 | No | No |
| 17478235 | PPARG Modulators for the Treatment of Osteoporosis | September 2021 | May 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17469111 | POLYVALENT STING ACTIVATING COMPOSITIONS AND USES THEREOF | September 2021 | October 2023 | Allow | 25 | 0 | 0 | Yes | No |
| 17459838 | DEUTERATED ETORICOXIB, METHODS OF MANUFACTURE, AND USE THEREOF | August 2021 | October 2023 | Allow | 26 | 1 | 0 | No | No |
| 17409377 | ORGANIC COMPOUNDS | August 2021 | August 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17407418 | KRAS mutant protein inhibitors | August 2021 | December 2021 | Allow | 4 | 1 | 0 | No | No |
| 17398408 | CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE | August 2021 | July 2023 | Allow | 23 | 1 | 0 | No | No |
| 17391586 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | August 2021 | January 2024 | Allow | 29 | 2 | 0 | No | No |
| 17427487 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | July 2021 | September 2022 | Allow | 13 | 1 | 0 | Yes | No |
| 17365503 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF | July 2021 | June 2024 | Allow | 35 | 2 | 1 | No | No |
| 17358991 | SOLID FORMS OF AN HPK1 INHIBITOR | June 2021 | June 2023 | Allow | 23 | 1 | 0 | No | No |
| 17356370 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | June 2021 | December 2022 | Allow | 18 | 1 | 0 | No | No |
| 17348942 | Diagnostic Assay and Treatment for Preeclampsia | June 2021 | January 2024 | Allow | 31 | 1 | 0 | No | No |
| 17341916 | METHODS AND COMPOSITIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS | June 2021 | October 2021 | Allow | 5 | 1 | 0 | No | No |
| 17339563 | SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY | June 2021 | March 2023 | Allow | 22 | 3 | 1 | No | No |
| 17335565 | IRON/SHIKONIN NANO-COMPOSITE AND USE THEREOF AND METHOD FOR PREPARING THE SAME BY SUPERMOLECULAR SELF-ASSEMBLY | June 2021 | January 2023 | Allow | 20 | 1 | 0 | No | No |
| 17328091 | METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION | May 2021 | October 2023 | Allow | 29 | 1 | 0 | No | No |
| 17326159 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | May 2021 | January 2024 | Allow | 32 | 2 | 0 | No | No |
| 17314753 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | May 2021 | June 2023 | Allow | 25 | 1 | 0 | No | No |
| 17291791 | NEW SELECTIVE MODULATORS OF INSECT NICOTINIC ACETYLCHOLINE RECEPTORS | May 2021 | August 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17245216 | TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF | April 2021 | August 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17243872 | INHIBITORS OF CXCR2 | April 2021 | September 2023 | Allow | 29 | 1 | 0 | No | No |
| 17242867 | CXCL10 Inhibitors | April 2021 | June 2022 | Abandon | 14 | 2 | 1 | No | No |
| 17240446 | DEUTERATED ETORICOXIB, METHODS OF MANUFACTURE, AND USE THEREOF | April 2021 | August 2021 | Allow | 3 | 0 | 0 | No | No |
| 17238529 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | April 2021 | October 2023 | Allow | 30 | 1 | 0 | No | No |
| 17238525 | COMPOSITIONS COMPRISING AN UROLITHIN COMPOUND | April 2021 | September 2023 | Allow | 29 | 1 | 0 | No | No |
| 17237497 | Nasal Spray Composition | April 2021 | November 2022 | Allow | 19 | 2 | 1 | No | No |
| 17236235 | METHODS OF TREATING COGNITIVE IMPAIRMENT OR IMPROVING COGNITIVE FUNCTION | April 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17282109 | MICROBIOCIDAL QUINOLINE DIHYDRO-(THIAZINE)OXAZINE DERIVATIVES | April 2021 | February 2024 | Allow | 34 | 0 | 0 | No | No |
| 17219394 | METHODS AND COMPOSITIONS FOR TREATING CANCER | March 2021 | August 2022 | Allow | 17 | 4 | 0 | Yes | No |
| 17215468 | Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors | March 2021 | February 2023 | Allow | 23 | 2 | 0 | No | No |
| 17197095 | KRAS mutant protein inhibitors | March 2021 | July 2021 | Allow | 4 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAVIS, BRIAN J.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner DAVIS, BRIAN J works in Art Unit 1612 and has examined 540 patent applications in our dataset. With an allowance rate of 86.7%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 17 months.
Examiner DAVIS, BRIAN J's allowance rate of 86.7% places them in the 60% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by DAVIS, BRIAN J receive 1.37 office actions before reaching final disposition. This places the examiner in the 29% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by DAVIS, BRIAN J is 17 months. This places the examiner in the 96% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +8.0% benefit to allowance rate for applications examined by DAVIS, BRIAN J. This interview benefit is in the 40% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 37.6% of applications are subsequently allowed. This success rate is in the 83% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 61.6% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 40.5% are granted (fully or in part). This grant rate is in the 40% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.1% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.